Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Non-Current Deferred Tax Liability (2018 - 2022)

Historic Non-Current Deferred Tax Liability for Exagen (XGN) over the last 5 years, with Q4 2022 value amounting to $1.4 million.

  • Exagen's Non-Current Deferred Tax Liability rose 3695.44% to $1.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.4 million, marking a year-over-year increase of 3695.44%. This contributed to the annual value of $1.4 million for FY2022, which is 3695.44% up from last year.
  • According to the latest figures from Q4 2022, Exagen's Non-Current Deferred Tax Liability is $1.4 million, which was up 3695.44% from $306000.0 recorded in Q3 2022.
  • In the past 5 years, Exagen's Non-Current Deferred Tax Liability ranged from a high of $1.4 million in Q4 2022 and a low of $147000.0 during Q1 2020
  • Its 5-year average for Non-Current Deferred Tax Liability is $448000.0, with a median of $306000.0 in 2022.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first tumbled by 4000.0% in 2020, then skyrocketed by 9367.09% in 2022.
  • Over the past 5 years, Exagen's Non-Current Deferred Tax Liability (Quarter) stood at $672000.0 in 2018, then grew by 8.93% to $732000.0 in 2019, then rose by 8.61% to $795000.0 in 2020, then rose by 29.69% to $1.0 million in 2021, then soared by 36.95% to $1.4 million in 2022.
  • Its Non-Current Deferred Tax Liability stands at $1.4 million for Q4 2022, versus $306000.0 for Q3 2022 and $306000.0 for Q2 2022.